FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. PMID 40334149 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial. PMID 40294349 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. PMID 40239133 · J Clin Oncol · 2025-Jun-20 The record describes a randomized trial with a primary time-to-event efficacy endpoint (PFS) and reports formal interim results with HR and median survival times. The phase is not explicitly labeled as 'Phase III' in the provided metadata, but the trial design (multicenter, 109 patients, standard comparator) and definitive interim analysis supporting a conclusion of 'standard initial therapy' are consistent with a Phase III/IIIb definitive trial. Therefore, eligibility is confirmed. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study. PMID 40112876 · Br J Dermatol · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. PMID 39862230 · Br J Dermatol · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial. PMID 39385327 · Chin Med J (Engl) · 2025-Jun-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 4 Panel · risk unclear |
| Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients. PMID 40573987 · Vaccines (Basel) · 2025-Jun-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Multicentre, Double-Blind, Randomised, Non-Inferiority Trial of a Novel Single-Injection Intra-Articular HMDA-Cross-Linked Hyaluronate Gel for Knee Osteoarthritis. PMID 40566128 · J Clin Med · 2025-Jun-19 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial. PMID 40537275 · RMD Open · 2025-Jun-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. PMID 40293180 · N Engl J Med · 2025-Jun-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. PMID 40202593 · N Engl J Med · 2025-Jun-19 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Pragmatic Grouping Model for Bone-Only De Novo Metastatic Breast Cancer (MetS Protocol MF22-03). PMID 40563682 · Cancers (Basel) · 2025-Jun-18 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 3 Figure · 5 Panel · risk not_visible |
| Efficacy of Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Trials. PMID 40530428 · Int J Low Extrem Wounds · 2025-Jun-18 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial. PMID 40367619 · Eur J Cancer · 2025-Jun-18 The record is a sub-analysis of the APHINITY trial focusing on BMI and weight changes, not the original primary result report of the randomized trial's efficacy. It is a subgroup/post-hoc analysis, which is excluded per the adjudication rules. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial. PMID 40528226 · Trials · 2025-Jun-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. PMID 40480221 · Cell Rep Med · 2025-Jun-17 The record describes an original, randomized, Phase III oncology trial with drug interventions. However, the primary endpoint is pathological complete response (pCR), a binary categorical outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). There is no signal of Kaplan-Meier analysis or hazard ratios for a time-to-event endpoint in the abstract or metadata. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Accelerated Radiotherapy for Complicated Bone Metastases: SHARON Bone Randomized Phase III Trial Shows Non-Inferiority Compared to Standard Palliative Fractionation (NCT03503682). PMID 40563650 · Cancers (Basel) · 2025-Jun-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults. PMID 40246546 · Aesthet Surg J · 2025-Jun-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. PMID 40526078 · Cancer · 2025-Jun-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of Condoliase on Health-related Quality of Life in Participants With Radicular Leg Pain Associated With Lumbar Disk Herniation: Results From a United States Phase 3 Clinical Trial. PMID 40066868 · Spine (Phila Pa 1976) · 2025-Jun-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial. PMID 40517007 · Lancet · 2025-Jun-14 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Prophylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm. PMID 40515786 · Eur J Pediatr · 2025-Jun-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. PMID 40473449 · Lancet · 2025-Jun-14 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Evaluation of machine-learning models to measure individualized treatment effects from randomized clinical trial data with time-to-event outcomes. PMID 40980764 · ArXiv · 2025-Jun-13 The record describes a methodological study evaluating machine learning models using data from randomized trials, but it is not itself a report of an original randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. It lacks explicit Phase III/IIIb or Phase II/III trial evidence and does not report on a specific drug-containing intervention's efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Effectiveness of Group and Individual Training in Emotional Freedom Techniques for Patients in Remission from Melanoma: A Randomized Controlled Trial. PMID 40565447 · Healthcare (Basel) · 2025-Jun-13 The study is a randomized controlled trial in human melanoma survivors. It is not a drug intervention trial (evaluates Emotional Freedom Techniques). It does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR); outcomes are psychological/wellbeing measures from questionnaires and distress scores. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Epigallocatechin Gallate in the Treatment and Prevention of Dermatitis: A Systematic Review. PMID 40564177 · Biomedicines · 2025-Jun-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Hangeshashinto in delaying grade 2 radiotherapy-induced mucositis development in patients with hypopharyngeal or laryngeal cancer: Preliminary finding of a randomized clinical trial. PMID 40527845 · Medicine (Baltimore) · 2025-Jun-13 The study is an oncology, human, randomized trial with a time-to-event endpoint (Kaplan-Meier) and a drug intervention (herbal medicine). However, it fails the key criterion of being a Phase III/IIIb or Phase II/III trial. The metadata and abstract indicate it is a preliminary, single-center study, with no explicit mention of Phase III. Therefore, it does not meet the eligibility requirement for definitive phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study. PMID 40514717 · Arthritis Res Ther · 2025-Jun-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Return to care of children and adolescents living with HIV who missed their clinic visits or were lost to follow-up: a continuous quality improvement study in Uganda. PMID 40514054 · BMJ Open Qual · 2025-Jun-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer. PMID 40358364 · Clin Cancer Res · 2025-Jun-13 The study is a randomized Phase II window-of-opportunity study evaluating a biomarker (PARP inhibition) as the primary objective, not a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. PMID 40227186 · Clin Cancer Res · 2025-Jun-13 The study is an oncology randomized trial with drug intervention and reports OS as a co-primary endpoint, but the abstract does not present any OS results (e.g., survival curves, median, HR) – it only reports organ preservation rates. Furthermore, the trial phase is not confirmed as Phase III or definitive; it appears to be a smaller randomized study possibly Phase II. Therefore, it lacks the explicit Phase III/IIIb or Phase II/III designation and the required time-to-event efficacy results for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial. PMID 40192715 · Clin Cancer Res · 2025-Jun-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation. PMID 40162917 · Clin Cancer Res · 2025-Jun-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 3 Panel · risk unclear |
| HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study. PMID 39892383 · Med · 2025-Jun-13 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. PMID 39326009 · Inflamm Bowel Dis · 2025-Jun-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Combined Hyperthermic Intraperitoneal Chemotherapy and Normothermic Intraperitoneal Chemotherapy Long-Term After Interval Cytoreduction in Ovarian Cancer: A Phase I Clinical Trial (BICOV1). PMID 40563606 · Cancers (Basel) · 2025-Jun-12 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| [Effect of electroacupuncture on intestinal function after gastric cancer surgery]. PMID 40518778 · Zhongguo Zhen Jiu · 2025-Jun-12 The study is a randomized trial in oncology (gastric cancer surgery) but does not meet key eligibility criteria: 1) The intervention is electroacupuncture combined with enhanced recovery after surgery (ERAS), not a drug-containing intervention. 2) The primary endpoints are functional recovery metrics (intestinal motility, tolerance to oral intake) and inflammatory markers, not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or any analysis with Kaplan-Meier curves or hazard ratios. 3) The trial phase is not specified, but based on the context (post-surgical adjuvant care), it is unlikely to be a Phase III/IIIb or Phase II/III trial of a drug. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous versus intravenous route switch from oral to parenteral morphine in patients with cancer: randomised controlled trial. PMID 40506094 · BMJ Support Palliat Care · 2025-Jun-12 The study is a randomized trial in cancer patients, but it does not meet key eligibility criteria: (1) The intervention compares subcutaneous vs. intravenous administration routes for morphine, not a drug vs. control; (2) The time-to-event endpoints (time to stable infusion rate, time to pain relief) are not standard oncology efficacy endpoints like OS, PFS, etc.; (3) The trial phase is not specified, and it is not clearly a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Employing skin self-examination and fear of cancer recurrence management in early-stage melanoma follow-up: evaluation of the MELACARE intervention in a randomised controlled trial. PMID 40504479 · J Cancer Surviv · 2025-Jun-12 The study is an oncology, human, randomized controlled trial with original results, but it is excluded because it evaluates a non-drug intervention (nurse-led follow-up program) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. PMID 40504283 · J Neurol · 2025-Jun-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. PMID 40421736 · N Engl J Med · 2025-Jun-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Nerandomilast in Patients with Progressive Pulmonary Fibrosis. PMID 40388329 · N Engl J Med · 2025-Jun-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. PMID 40387033 · N Engl J Med · 2025-Jun-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. PMID 40090011 · Blood · 2025-Jun-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial. PMID 40558655 · J Cardiovasc Dev Dis · 2025-Jun-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. PMID 40500695 · Mol Cancer · 2025-Jun-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Home-based online exercise training and chronic, low-grade inflammation in cancer patients after curative surgery: secondary analysis of the randomized controlled multicenter CRBP-TS trial. PMID 40498221 · Support Care Cancer · 2025-Jun-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lung cancer screening in Finland: a prospective randomized trial. PMID 40497290 · Acta Oncol · 2025-Jun-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Non-randomised prospective clinical trial to improve follow-up adherence, survivorship knowledge and late effects documentation at a childhood cancer clinic in Western Kenya: a study protocol. PMID 40499965 · BMJ Open · 2025-Jun-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Clinical effect of ePRO-based symptom monitoring and management on improving survival outcomes in patients with advanced cancer: a single-centre, prospective, randomised controlled trial protocol. PMID 40499961 · BMJ Open · 2025-Jun-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |